Caris Life Sciences, Inc. (CAI) Comparison with companies in other sectors?

Caris Life Sciences, Inc. has a share price of 277.93M. You can analyze Caris Life Sciences, Inc. (CAI) competitors across different market sectors through stock heatmaps.

What are CAI's NET and operating margins?

Caris Life Sciences, Inc. (CAI) operating margin is around 0.47, and net profit margin is approximately 0.09 as of the latest reports.

In what way does CAI's earnings per share (EPS) trend reflect its financial momentum?

Caris Life Sciences, Inc. (CAI) EPS is -2.57 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Caris Life Sciences, Inc. is -11.49, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Caris Life Sciences, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Caris Life Sciences, Inc. like P/E which is 19.08, P/B which is 0.75, and PEG which is 0.19. Compare them with sector averages to evaluate if the stock is priced fairly.

Caris Life Sciences, Inc.

CAI•NASDAQ

Healthcare

Biotechnology

$29.54

$0.05(0.17%)

Fundamental Analysis of Caris Life Sciences, Inc. (CAI)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-2.57

P/E Ratio

-11.49

ROE

0.04%

Net Margin

0.09%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$8.21B

Shares OutstandingTotal number of shares issued

$277.93M

Book Value/ShareNet worth per share

$39.12

Revenue/ShareAnnual revenue per share

$16.38

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-2.57

Net MarginNet income as percentage of revenue

9.43%

Operating MarginOperating income as percentage of revenue

47.31%

ROEReturn on shareholders' equity

3.97%

ROAReturn on total assets

1.06%

ROCEReturn on capital employed

6.07%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$3.21

Cash/ShareCash and equivalents per share

$7.38

FCF YieldFree cash flow as percentage of market cap

0.70%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for CAIFinancial Ratios Analysis details for CAI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CAISector Benchmarking details for CAI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Caris Life Sciences, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Caris Life Sciences, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Caris Life Sciences, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Caris Life Sciences, Inc.

For Caris Life Sciences, Inc., essential financial indicators include EPS -2.57, PE -11.49, and ROE 0.04. These key ratios reveal insights into Caris Life Sciences, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Caris Life Sciences, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Caris Life Sciences, Inc.

Metrics like Net Margin 9.43% and ROA 1.06% shed light on how well Caris Life Sciences, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Caris Life Sciences, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Caris Life Sciences, Inc.

Using ratios such as P/B Ratio 0.75 and PEG Ratio 0.19, investors can assess whether Caris Life Sciences, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Caris Life Sciences, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Caris Life Sciences, Inc.

Financial health indicators, such as Debt/Equity Ratio 2.49 and Cash Flow $3.21, provide a snapshot of Caris Life Sciences, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Caris Life Sciences, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Caris Life Sciences, Inc.

Investing in Caris Life Sciences, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Caris Life Sciences, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;